BASKING RIDGE, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, Ph.D., President and Chief Executive Officer of Lisata, will provide a corporate overview in a pre-recorded, on-demand presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The confe ...

Core Insights - re+PLAY is a CBD wellness brand founded by NBA veteran Al Harrington, utilizing Avicanna's proprietary CBD formulations [1][2] - The brand's initial product launch in the United States includes two products available online and at select retailers [1][2] - The collaboration between Avicanna LATAM SAS and Harrington Wellness focuses on developing CBD-based topicals for the athletic community [3][4] Company Overview - Avicanna LATAM SAS is a biopharmaceutical company based in Colombia, specializing in plant-derived cannabinoid products [2][6] - The company has a scientific platform that supports the development and commercialization of over thirty proprietary cannabinoid-based products [6] - Avicanna's subsidiaries include Santa Marta Golden Hemp, which provides high-quality CBD, THC, and CBG for various applications [6][7] Product Details - Initial re+PLAY products include a 3% CBD localized cream and a 2% CBD and 1% CBG transdermal gel, utilizing patented deep tissue technology [5] - The CBD and CBG in these formulations are derived from USDA organic certified hemp cultivated in Colombia [5] - The re+PLAY brand emphasizes THC-free products that have been endorsed by medical professionals and athletes [8]

Core Insights - The iShares U.S. Pharmaceuticals ETF (IHE) is a passively managed fund launched on May 1, 2006, aimed at providing broad exposure to the Healthcare - Pharma segment of the equity market [1] - The Healthcare - Pharma sector is ranked 7th among the 16 Zacks sectors, placing it in the top 44% [2] Fund Overview - Sponsored by Blackrock, IHE has assets exceeding $578.73 million, categorizing it as an average-sized ETF [3] - The fund seeks to match the performance of the Dow Jones U.S. Select Pharmaceuticals Index, which is a free-float adjusted market capitalization-weighted index [4] Cost Structure - IHE has an annual operating expense ratio of 0.38%, making it one of the cheaper options in the ETF space [5] - The ETF offers a 12-month trailing dividend yield of 1.64% [5] Sector Exposure and Holdings - The ETF is fully allocated to the Healthcare sector, with approximately 100% of its portfolio [6] - Johnson & Johnson (JNJ) constitutes about 25.45% of total assets, followed by Eli Lilly (LLY) and Viatris Inc (VTRS), with the top 10 holdings accounting for approximately 78.07% of total assets [7] Performance Metrics - As of September 2, 2025, IHE has gained roughly 9.19% this year but is down about 0.74% over the past year [8] - The ETF has traded between $61 and $72.85 in the last 52 weeks, with a beta of 0.54 and a standard deviation of 15.83% over the trailing three-year period, indicating a higher risk profile [8] Alternatives - IHE carries a Zacks ETF Rank of 3 (Hold), suggesting it is a reasonable option for investors seeking exposure to the Healthcare ETFs area [9] - Other ETF options include Invesco Pharmaceuticals ETF (PJP) and VanEck Pharmaceutical ETF (PPH), with respective assets of $259.99 million and $620.64 million [10]

WEST CHESTER, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York City. H.C. Wainwright 27th Annual Global Investment Conference, September 8-10, ...

At Wide Moat Research, there are several key principles that guide our approach to investing. We believe these are instrumental to long-term investing success.Hi, my name is Kody. Aside from my articles here on Seeking Alpha, I am also a regular contributor to Sure Dividend, The Dividend Kings, and iREIT+Hoya Capital. I have been investing since September 2017 (age 20) and interested in dividend investing since about 2009.Since July 2018, I have ran Kody's Dividends. This is a blog that is documenting my jo ...

Core Viewpoint - The announcement highlights that Jiangsu Shenhua Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Huaren Health, has received the acceptance notice for the drug registration application of Fumaric Acid Vonoprazan Tablets from the National Medical Products Administration of China, indicating a significant step towards market entry for this new medication [1] Group 1: Drug Information - Fumaric Acid Vonoprazan is a novel potassium-competitive acid blocker (P-CAB) that can reversibly inhibit the H+/K+-ATPase on gastric parietal cells in a potassium-competitive manner without relying on an acidic environment [1] - The drug is stable in highly acidic environments and can rapidly, effectively, and durably suppress gastric acid secretion from gastric parietal cells, significantly reducing the occurrence of nighttime gastric acid elevation [1] - It was officially approved for marketing in China on December 18, 2019, for the treatment of gastroesophageal reflux disease, making it the first P-CAB to enter the Chinese market [1]

Core Viewpoint - Servier and IDEAYA Biosciences have entered into an exclusive license agreement for darovasertib, a treatment for uveal melanoma, granting Servier regulatory and commercial rights outside the United States while IDEAYA retains rights in the U.S. [1][7] Company Overview - Servier is an independent international pharmaceutical group focused on delivering transformative therapies and has a strong commitment to oncology, allocating nearly 70% of its R&D budget to this field [10][12] - IDEAYA Biosciences specializes in precision medicine for oncology, focusing on the discovery and development of targeted therapies aligned with genetic drivers of cancer [14] Product Development - Darovasertib is a selective protein kinase C (PKC) inhibitor aimed at treating primary and metastatic uveal melanoma, which is a rare and aggressive form of eye cancer [1][5] - The drug has received Breakthrough Therapy Designation and Fast Track designation from the US FDA, indicating its potential as a significant treatment option [6] Financial Terms of the Agreement - IDEAYA will receive an upfront payment of $210 million, with potential additional payments of up to $320 million based on regulatory and commercial milestones, plus double-digit royalties on net sales outside the U.S. [7][8] Clinical Trials - Darovasertib is currently undergoing multiple global clinical trials, including a Phase 2/3 trial in combination with crizotinib and a Phase 3 trial evaluating it as a monotherapy [4][6] - A global Phase 3 randomized clinical trial is planned for 2026 to assess adjuvant darovasertib in primary uveal melanoma patients [4]

SHANGHAI, Sept. 2, 2025 /PRNewswire/ -- Peptides have recently emerged at the forefront of therapeutic innovation, with cyclic peptides gaining particular attention for their ability to bridge the gap between small molecules and large biologics. Positioned between the two, cyclic peptides combine the oral potential of small molecules with the structural advantages of biologics—making them ideally suited to address traditionally "undruggable" protein–protein interactions and complex receptors, while opening ...

Core Viewpoint - Reponex Pharmaceuticals A/S has received regulatory approval to initiate a pivotal Phase 2 clinical trial for RNX-011, targeting secondary peritonitis, a serious intra-abdominal infection with high mortality rates [2][3]. Group 1: Regulatory Approval and Study Design - The approval marks a significant milestone for the company and validates the scientific strategy behind RNX-011 [3]. - The study is a randomized, placebo-controlled trial that will investigate a triple-action combination therapy (fosfomycin, metronidazole, and GM-CSF) administered directly into the abdominal cavity during surgery [4]. - The trial aims to enroll 32 patients, with the first patient expected to be included in Q4 2025 [6]. Group 2: Study Objectives and Expected Outcomes - The primary objective of the study is to demonstrate that RNX-011 can reduce serious postoperative complications, such as abscesses and the need for re-operation, which are critical for potential partners and payers [5]. - The study will also assess the treatment's effect on local inflammation (IL-6) and overall patient recovery (QoR-15) to provide strong mechanistic data supporting clinical efficacy [5]. Group 3: Company Strategy and Future Outlook - The regulatory approval is viewed as a crucial commercial milestone, transitioning from proof-of-concept to a pivotal study that aims to deliver data required by major pharmaceutical companies [7]. - Pharma Equity Group is committed to supporting Reponex Pharmaceuticals in advancing its medical projects, focusing on innovative solutions and breakthrough therapies [9][10].

Core Insights - The article highlights the challenge of finding high-yield dividend stocks in a buoyant stock market, emphasizing the potential of Realty Income, Healthpeak Properties, and Pfizer as attractive options for passive income generation. Group 1: Realty Income - Realty Income has seen its shares fall approximately 22% from their peak in 2022, yet it continues to raise its dividend payout, currently offering a 5.5% yield with a history of steady payout growth [4][5]. - The company makes monthly dividend payments and has raised its payout every quarter except one since going public over 30 years ago, despite facing challenges from rising interest rates [5]. - Realty Income's portfolio consists of 15,606 properties, and it only accounts for about 4% of the U.S. net lease REIT market, indicating significant growth potential, especially in Europe where it has a minimal market share [6]. Group 2: Healthpeak Properties - Healthpeak Properties, a net lease REIT, focuses on renting laboratory space to pharmaceutical and biotech companies and recently merged with Physicians Realty to enhance its portfolio [7][8]. - Following the merger, Healthpeak's stock price has declined, allowing it to offer a 6.8% dividend yield, despite a decrease in demand for laboratory space [8]. - The company expects funds from operations to be between $1.78 and $1.84 per share this year, which is sufficient to support its current annualized payout of $1.22 per share [9]. Group 3: Pfizer - Pfizer's shares have decreased about 60% from their all-time high during the COVID-19 pandemic, primarily due to declining sales of COVID-19 products and upcoming patent cliffs [10]. - Despite the stock price drop, Pfizer raised its dividend for the 16th consecutive year, currently offering a 6.9% yield [10]. - The company anticipates losing patent protection for key products, which could reduce annual sales by $17 billion to $18 billion between 2026 and 2028, but it has invested in new products expected to generate $20 billion in annual sales by 2030 [11][12].